Annualized rate of exacerbations reduced across two randomized trials in severe asthma with eosinophilic phenotype<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Sept. 10, 2024 (HealthDay News) — For patients with severe asthma with an eosinophilic phenotype, depemokimab reduces the annualized rate of exacerbations, according to a study published online Sept. 9 in the New England Journal of Medicine <\/em>to coincide with the European Respiratory Society Congress, held from Sept. 7 to 11 in Vienna.<\/p>\n David J. Jackson, Ph.D., from King’s College London, and colleagues examined the efficacy and safety of depemokimab in patients with severe asthma and an eosinophilic phenotype characterized by a high eosinophil count and a history of exacerbations despite receipt of medium- or high-dose inhaled glucocorticoids. Participants across two trials were randomly allocated to receive depemokimab (100 mg subcutaneously) or placebo at weeks 0 and 26, plus standard care (502 and 260, respectively).<\/p>\n The researchers found that the annualized rate of exacerbations was 0.46 and 1.11 with depemokimab and placebo, respectively, in SWIFT-1 and 0.56 and 1.08, respectively, in SWIFT-2 (rate ratios, 0.42 and 0.52). The change from baseline in the score on the St. George’s Respiratory Questionnaire did not differ significantly between groups in either trial. Both groups had a similar proportion of patients with any adverse event.<\/p>\n “The administration of depemokimab every six months reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype,” the authors write.<\/p>\n Two authors disclosed ties to GSK, which funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n